NCT03086616View on ClinicalTrials.gov

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

October 4, 2021

Study Completion Date

October 4, 2021

Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
DRUG

Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)

Nal-IRI will be given directly into the tumor using CED.

Trial Locations (1)

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

The V Foundation for Cancer Research

OTHER

collaborator

Pacific Pediatric Neuro-Oncology Consortium

OTHER

lead

Sabine Mueller, MD, PhD

OTHER

NCT03086616 - CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009) | Biotech Hunter | Biotech Hunter